keyword
https://read.qxmd.com/read/37418295/dual-piperidine-based-histamine-h-3-and-sigma-1-receptor-ligands-in-the-treatment-of-nociceptive-and-neuropathic-pain
#21
JOURNAL ARTICLE
Katarzyna Szczepańska, Tadeusz Karcz, Maria Dichiara, Szczepan Mogilski, Justyna Kalinowska-Tłuścik, Bogusław Pilarski, Arkadiusz Leniak, Wojciech Pietruś, Sabina Podlewska, Katarzyna Popiołek-Barczyk, Laura J Humphrys, M Carmen Ruiz-Cantero, David Reiner-Link, Luisa Leitzbach, Dorota Łażewska, Steffen Pockes, Michał Górka, Adam Zmysłowski, Thierry Calmels, Enrique J Cobos, Agostino Marrazzo, Holger Stark, Andrzej J Bojarski, Emanuele Amata, Katarzyna Kieć-Kononowicz
In search of new dual-acting histamine H3 /sigma-1 receptor ligands, we designed a series of compounds structurally based on highly active in vivo ligands previously studied and described by our team. However, we kept in mind that within the previous series, a pair of closely related compounds, KSK67 and KSK68 , differing only in the piperazine/piperidine moiety in the structural core showed a significantly different affinity at sigma-1 receptors (σ1 Rs). Therefore, we first focused on an in-depth analysis of the protonation states of piperazine and piperidine derivatives in the studied compounds...
July 7, 2023: Journal of Medicinal Chemistry
https://read.qxmd.com/read/37329185/the-histamine-system-and-cognitive-function-an-in-vivo-h3-receptor-pet-imaging-study-in-healthy-volunteers-and-patients-with-schizophrenia
#22
JOURNAL ARTICLE
Atheeshaan Arumuham, Matthew M Nour, Mattia Veronese, Ellis Chika Onwordi, Eugenii A Rabiner, Oliver D Howes
BACKGROUND: The histamine-3 receptor (H3R) is an auto- and heteroreceptor that inhibits the release of histamine and other neurotransmitters. Post-mortem evidence has found altered H3R expression in patients with psychotic disorders, which may underlie cognitive impairment associated with schizophrenia (CIAS). AIMS: We used positron emission tomography (PET) imaging to compare brain uptake of an H3R selective tracer between patients with schizophrenia and matched controls (healthy individuals)...
June 16, 2023: Journal of Psychopharmacology
https://read.qxmd.com/read/37298094/epigenetic-histone-methylation-of-ppar%C3%AE-and-cpt1a-signaling-contributes-to-betahistine-preventing-olanzapine-induced-dyslipidemia
#23
JOURNAL ARTICLE
Yueqing Su, Chao Deng, Xuemei Liu, Jiamei Lian
As a partial histamine H1 receptor agonist and H3 antagonist, betahistine has been reported to partially prevent olanzapine-induced dyslipidemia and obesity through a combination therapy, although the underlying epigenetic mechanisms are still not known. Recent studies have revealed that histone regulation of key genes for lipogenesis and adipogenesis in the liver is one of the crucial mechanisms for olanzapine-induced metabolic disorders. This study investigated the role of epigenetic histone regulation in betahistine co-treatment preventing dyslipidemia and fatty liver caused by chronic olanzapine treatment in a rat model...
May 23, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/37256468/imbalance-of-multiple-neurotransmitter-pathways-leading-to-depression-like-behavior-and-cognitive-dysfunction-in-the-triple-transgenic-mouse-model-of-alzheimer-disease
#24
JOURNAL ARTICLE
Meng Zhang, Li-Yuan Liu, Yong Xu, Wen-Zhi Wang, Nian-Zhuang Qiu, Fang-Fang Zhang, Feng Zhang, Xiao-Dan Wang, Wei Chen, Xiao-Yan Xu, Yong-Feng Gao, Mei-Hua Chen, Yu-Qin Li, Han-Ting Zhang, Hao Wang
Depression is among the most frequent psychiatric comorbid conditions in Alzheimer disease (AD). However, pharmacotherapy for depressive disorders in AD is still a big challenge, and the data on the efffcacy of current antidepressants used clinically for depressive symptoms in patients with AD remain inconclusive. Here we investigated the mechanism of the interactions between depression and AD, which we believe would aid in the development of pharmacological therapeutics for the comorbidity of depression and AD...
May 31, 2023: Metabolic Brain Disease
https://read.qxmd.com/read/37242517/function-and-role-of-histamine-h-1-receptor-in-the-mammalian-heart
#25
REVIEW
Joachim Neumann, Britt Hofmann, Uwe Kirchhefer, Stefan Dhein, Ulrich Gergs
Histamine can change the force of cardiac contraction and alter the beating rate in mammals, including humans. However, striking species and regional differences have been observed. Depending on the species and the cardiac region (atrium versus ventricle) studied, the contractile, chronotropic, dromotropic, and bathmotropic effects of histamine vary. Histamine is present and is produced in the mammalian heart. Thus, histamine may exert autocrine or paracrine effects in the mammalian heart. Histamine uses at least four heptahelical receptors: H1 , H2 , H3 and H4 ...
May 11, 2023: Pharmaceuticals
https://read.qxmd.com/read/37242458/guanidines-synthesis-of-novel-histamine-h-3-r-antagonists-with-additional-breast-anticancer-activity-and-cholinesterases-inhibitory-effect
#26
JOURNAL ARTICLE
Marek Staszewski, Magdalena Iwan, Tobias Werner, Marek Bajda, Justyna Godyń, Gniewomir Latacz, Agnieszka Korga-Plewko, Joanna Kubik, Natalia Szałaj, Holger Stark, Barbara Malawska, Anna Więckowska, Krzysztof Walczyński
This study examines the properties of novel guanidines, designed and synthesized as histamine H3 R antagonists/inverse agonists with additional pharmacological targets. We evaluated their potential against two targets viz., inhibition of MDA-MB-231, and MCF-7 breast cancer cells viability and inhibition of AChE/BuChE. ADS10310 showed micromolar cytotoxicity against breast cancer cells, combined with nanomolar affinity at h H3 R, and may represent a promising target for the development of an alternative method of cancer therapy...
April 30, 2023: Pharmaceuticals
https://read.qxmd.com/read/37240671/migraine-allergy-and-histamine-is-there-a-link
#27
REVIEW
Alessandro Ferretti, Mattia Gatto, Margherita Velardi, Giovanni Di Nardo, Thomas Foiadelli, Gianluca Terrin, Manuela Cecili, Umberto Raucci, Massimiliano Valeriani, Pasquale Parisi
The relationship between migraines and allergies is controversial. Though they are epidemiologically linked, the underlying pathophysiological connection between them remains unclear. Migraines and allergic disorders have various underlying genetic and biological causes. As per the literature, these conditions are epidemiologically linked, and some common pathophysiological pathways have been hypothesized. The histaminergic system may be the clue to understanding the correlation among these diseases. As a neurotransmitter in the central nervous system with a vasodilatory effect, histamine has a well-documented influence on the allergic response and could be involved in the pathophysiology of migraines...
May 19, 2023: Journal of Clinical Medicine
https://read.qxmd.com/read/37233887/pitolisant-pediatric-first-approval
#28
REVIEW
Susan J Keam
Pitolisant (WAKIX® ), a histamine H3 receptor antagonist/inverse agonist that has been developed by Bioprojet Pharma, is approved in the EU and USA and elsewhere for use in adults with narcolepsy with or without cataplexy. In February 2023, based on clinical data in patients aged 6 to < 18 years, pitolisant received its first approval in adolescents and children from the age of 6 years for the treatment of narcolepsy with or without cataplexy in the EU. This article summarizes the milestones in the development of pitolisant leading to this pediatric first approval for narcolepsy with or without cataplexy...
July 2023: Paediatric Drugs
https://read.qxmd.com/read/37206665/snap25-differentially-contributes-to-g-i-o-coupled-receptor-function-at-glutamatergic-synapses-in-the-nucleus-accumbens
#29
JOURNAL ARTICLE
Kevin M Manz, José C Zepeda, Zack Zurawski, Heidi E Hamm, Brad A Grueter
The nucleus accumbens (NAc) guides reward-related motivated behavior implicated in pathological behavioral states, including addiction and depression. These behaviors depend on the precise neuromodulatory actions of Gi/o -coupled G-protein-coupled receptors (GPCRs) at glutamatergic synapses onto medium spiny projection neurons (MSNs). Previous work has shown that discrete classes of Gi/o -coupled GPCR mobilize Gβγ to inhibit vesicular neurotransmitter release via t-SNARE protein, SNAP25. However, it remains unknown which Gαi/o systems in the NAc utilize Gβγ-SNARE signaling to dampen glutamatergic transmission...
2023: Frontiers in Cellular Neuroscience
https://read.qxmd.com/read/37171719/p19-derived-neuronal-cells-express-h-1-h-2-and-h-3-histamine-receptors-a-biopharmaceutical-approach-to-evaluate-antihistamine-agents
#30
JOURNAL ARTICLE
Mariela Gomez Perez, Georgiana Tanasie, Armelle Tchoumi Neree, Narjara Gonzalez Suarez, Clara Lafortune, Joanne Paquin, Lucia Marcocci, Paola Pietrangeli, Borhane Annabi, Mircea Alexandru Mateescu
Histamine is a biogenic amine implicated in various biological and pathological processes. Convenient cellular models are needed to screen and develop new antihistamine agents. This report aimed to characterize the response of neurons differentiated from mouse P19 embryonal carcinoma cells to histamine treatment, and to investigate the modulation of this response by antihistamine drugs, vegetal diamine oxidase, and catalase. The exposure of P19 neurons to histamine reduced cell viability to 65% maximally. This effect involves specific histamine receptors, since it was prevented by treatment with desloratadine and cimetidine, respectively, H1 and H2 antagonists, but not by the H3 antagonist ciproxifan...
May 12, 2023: Amino Acids
https://read.qxmd.com/read/37171458/amelioration-of-cognition-impairments-in-the-valproic-acid-induced-animal-model-of-autism-by-ciproxifan-a-histamine-h3-receptor-antagonist
#31
JOURNAL ARTICLE
Farahnaz Taheri, Khadijeh Esmaeilpour, Gholamreza Sepehri, Vahid Sheibani, Majid Asadi Shekari
Autism spectrum disorder is a neurodevelopmental disorder characterized by deficits in social communication and repetitive behavior. Many studies show that the number of cognitive impairmentscan be reduced by antagonists of the histamine H3 receptor (H3R). In this study, the effects of ciproxifan (CPX) (1 and 3 mg/kg, intraperitoneally) on cognitive impairments in rat pups exposed to valproic acid (VPA) (600 mg/kg, intraperitoneally) wereexamined on postnatal day 48-50 (PND 48-50) using marble-burying task (MBT), open field, novel object recognition (NOR), and Passive avoidance tasks...
June 1, 2023: Behavioural Pharmacology
https://read.qxmd.com/read/37110645/antiseizure-properties-of-histamine-h-3-receptor-antagonists-belonging-3-4-dihydroquinolin-2-1-h-ones
#32
JOURNAL ARTICLE
Yi Hua, Mingxia Song, Qiaoyue Guo, Yiqin Luo, Xianqing Deng, Yushan Huang
H3 R is becoming an attractive and promising target for epilepsy treatment as well as the discovery of antiepileptics. In this work, a series of 6-aminoalkoxy-3,4-dihydroquinolin-2(1 H )-ones was prepared to screen their H3 R antagonistic activities and antiseizure effects. The majority of the target compounds displayed a potent H3 R antagonistic activity. Among them, compounds 2a , 2c , 2h , and 4a showed submicromolar H3 R antagonistic activity with an IC50 of 0.52, 0.47, 0.12, and 0.37 μM, respectively...
April 12, 2023: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://read.qxmd.com/read/37108661/evaluation-of-some-safety-parameters-of-dual-histamine-h-3-and-sigma-2-receptor-ligands-with-anti-obesity-potential
#33
JOURNAL ARTICLE
Kamil Mika, Małgorzata Szafarz, Marek Bednarski, Agata Siwek, Katarzyna Szczepańska, Katarzyna Kieć-Kononowicz, Magdalena Kotańska
Many studies have shown the high efficacy of histamine H3 receptor ligands in preventing weight gain. In addition to evaluating the efficacy of future drug candidates, it is very important to assess their safety profile, which is established through numerous tests and preclinical studies. The purpose of the present study was to evaluate the safety of histamine H3 /sigma-2 receptor ligands by assessing their effects on locomotor activity and motor coordination, as well as on the cardiac function, blood pressure, and plasma activity of certain cellular enzymes...
April 19, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/37086286/chronic-h-3-r-activation-reduces-l-dopa-induced-dyskinesia-normalizes-cortical-gaba-and-glutamate-levels-and-increases-striatal-dopamine-d-1-r-mrna-expression-in-6-hydroxydopamine-lesioned-male%C3%A2-rats
#34
JOURNAL ARTICLE
Alberto Avila-Luna, Arturo Gálvez-Rosas, Alexander Aguirre-Pérez, Alberto Hidalgo-Bravo, Alfonso Alfaro-Rodriguez, Camilo Ríos, José-Antonio Arias-Montaño, Antonio Bueno-Nava
RATIONALE: Dyskinesias induced by L-3,4-dihydroxyphenylalanine, L-Dopa (LIDs), are the major complication in the pharmacological treatment of Parkinson's disease. LIDs induce overactivity of the glutamatergic cortico-striatal projections, and drugs that reduce glutamatergic overactivity exert antidyskinetic actions. Chronic administration of immepip, agonist at histamine H3 receptors (H3 R), reduces LIDs and diminishes GABA and glutamate content in striatal dialysates (Avila-Luna et al...
April 22, 2023: Psychopharmacology
https://read.qxmd.com/read/37068253/ameliorating-parkinsonian-motor-dysfunction-by-targeting-histamine-receptors-in-entopeduncular-nucleus-thalamus-circuitry
#35
JOURNAL ARTICLE
Jian-Ya Peng, Zeng-Xin Qi, Qi Yan, Xiu-Juan Fan, Kang-Li Shen, Hui-Wei Huang, Jian-Hua Lu, Xiao-Qin Wang, Xiao-Xia Fang, Liming Mao, Jianguang Ni, Liang Chen, Qian-Xing Zhuang
In Parkinson's disease (PD), reduced dopamine levels in the basal ganglia have been associated with altered neuronal firing and motor dysfunction. It remains unclear whether the altered firing rate or pattern of basal ganglia neurons leads to parkinsonism-associated motor dysfunction. In the present study, we show that increased histaminergic innervation of the entopeduncular nucleus (EPN) in the mouse model of PD leads to activation of EPN parvalbumin (PV) neurons projecting to the thalamic motor nucleus via hyperpolarization-activated cyclic nucleotide-gated (HCN) channels coupled to postsynaptic H2 R...
April 25, 2023: Proceedings of the National Academy of Sciences of the United States of America
https://read.qxmd.com/read/37054563/post-translational-modifications-of-histone-proteins-by-monoamine-neurotransmitters
#36
REVIEW
Amni Al-Kachak, Ian Maze
Protein monoaminylation is a biochemical process through which biogenic monoamines (e.g., serotonin, dopamine, histamine, etc.) are covalently bonded to certain protein substrates via Transglutaminase 2, an enzyme that catalyzes the transamidation of primary amines to the γ-carboxamides of glutamine residues. Since their initial discovery, these unusual post-translational modifications have been implicated in a wide variety of biological processes, ranging from protein coagulation to platelet activation and G-protein signaling...
April 11, 2023: Current Opinion in Chemical Biology
https://read.qxmd.com/read/36989179/allergen-free-extracts-from-birch-ragweed-and-hazel-pollen-activate-human-and-guinea-pig-submucous-and-spinal-sensory-neurons
#37
JOURNAL ARTICLE
Sabine Buhner, Stefanie Schäuffele, Pieter Giesbertz, Ihsan Ekin Demir, Florian Zeller, Claudia Traidl-Hoffmann, Michael Schemann, Stefanie Gilles
BACKGROUND: Non-allergenic, low molecular weight components of pollen grains are suspected to trigger changes in gut functions, sometimes leading to inflammatory conditions. Based on extensive neuroimmune communication in the gut wall, we investigated the effects of aqueous pollen extracts (APE) on enteric and spinal sensory neurons. METHODS: Using Ca2+ and fast potentiometric imaging, we recorded the responses of guinea-pig and human submucous and guinea-pig dorsal root ganglion (DRG) neurons to microejection of low (<3 kDa) and high (≥3 kDa) molecular weight APEs of birch, ragweed, and hazel...
March 29, 2023: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
https://read.qxmd.com/read/36931805/safety-and-efficacy-of-pitolisant-in-children-aged-6-years-or-older-with-narcolepsy-with-or-without-cataplexy-a-double-blind-randomised-placebo-controlled-trial
#38
RANDOMIZED CONTROLLED TRIAL
Yves Dauvilliers, Michel Lecendreux, Gert Jan Lammers, Patricia Franco, Mikhail Poluektov, Christian Caussé, Isabelle Lecomte, Jeanne Marie Lecomte, Philippe Lehert, Jean Charles Schwartz, Giuseppe Plazzi
BACKGROUND: Narcolepsy is a life-long disorder characterised by excessive daytime sleepiness and cataplexy, often arising in childhood or adolescence. Pitolisant, a selective histamine H3 receptor inverse agonist, has been approved in Europe and USA for adults with narcolepsy with or without cataplexy, with a favourable safety profile. This phase 3 study aimed to assess the safety and efficacy of pitolisant in children with narcolepsy with or without cataplexy. METHODS: For this double-blind, randomised, placebo-controlled, multisite study, we recruited patients aged 6-17 years with narcolepsy with or without cataplexy in 11 sleep centres in five countries (Italy, France, Netherlands, Russia, and Finland)...
April 2023: Lancet Neurology
https://read.qxmd.com/read/36925216/histamine-promotes-angiogenesis-through-a-histamine-h1-receptor-pkc-vegf-mediated-pathway-in-human-endothelial-cells
#39
JOURNAL ARTICLE
Omer Faruk Hatipoglu, Takashi Nishinaka, Masahiro Nishibori, Masahiro Watanabe, Takao Toyomura, Shuji Mori, Kursat Oguz Yaykasli, Hidenori Wake, Hideo Takahashi
Histamine is a well-known inflammatory mediator, but how histamine induces angiogenesis remains poorly understood. In the present study, we demonstrated a dose-dependent dynamic tube formation in the human endothelial cell line EA.hy926 in the presence of histamine that was completely blocked by histamine H1 receptor (H1R) and protein kinase C (PKC) inhibitors. However, histamine H2, H3, and H4 receptor inhibitors did not inhibit tube formation, suggesting that H1R-PKC signaling is involved in histamine-induced tube formation...
April 2023: Journal of Pharmacological Sciences
https://read.qxmd.com/read/36903593/multitargeting-histamine-h-3-receptor-ligands-among-acetyl-and-propionyl-phenoxyalkyl-derivatives
#40
JOURNAL ARTICLE
Dorota Łażewska, Maria Kaleta, Paula Zaręba, Justyna Godyń, Mariam Dubiel, Ewelina Honkisz-Orzechowska, Agata Doroz-Płonka, Anna Więckowska, Holger Stark, Katarzyna Kieć-Kononowicz
Alzheimer's disease (AD) is a neurodegenerative disorder, for which there is no effective cure. Current drugs only slow down the course of the disease, and, therefore, there is an urgent need to find effective therapies that not only treat, but also prevent it. Acetylcholinesterase inhibitors (AChEIs), among others, have been used for years to treat AD. Histamine H3 receptors (H3 Rs) antagonists/inverse agonists are indicated for CNS diseases. Combining AChEIs with H3 R antagonism in one structure could bring a beneficial therapeutic effect...
March 3, 2023: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
keyword
keyword
45012
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.